Objective:
To discuss the FDA's de novo authorization of Notal Vision’s Scanly Home OCT device and its implications for monitoring neovascular age-related macular degeneration (nAMD).
Approach:
- FDA Authorization: The FDA granted de novo authorization to Notal Vision’s Scanly Home OCT device, which uses an AI-based Notal OCT Analyzer (NOA) to grade self-administered images.
- Pivotal Trial: A pivotal trial published in Ophthalmology Science validated the performance of the NOA for monitoring total retinal hyporeflective (TRO) volume in nAMD.
- Negotiations with FDA: The FDA required specific terminology regarding TRO volume, which is clinically equivalent to intra- and subretinal fluid, to achieve clearance.
- Subsequent Studies: Two additional studies published in Journal of ViteroRetinal Diseases and Retina supported the efficacy of home OCT.
Key Findings:
- The NOA's performance supports its use for monitoring TRO at home for nAMD management.
- The FDA's approval process involved negotiations over terminology related to fluid measurement.
- Inertia and financial concerns are cited as potential barriers to widespread adoption of home OCT among clinicians.
Interpretation:
Limitations:
- The impact of home OCT on in-office diagnostics is still unclear.
- Medicare has not yet established a reimbursement code for home OCT.
Conclusion:
The future of home monitoring for retinal disease patients will depend on reimbursement developments and clinician acceptance.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
